Darunavir
The Chinese authorities have indicated that Darunavir against 2019-nCoV may be successful. In vitro cell studies have shown that Darunavir can effectively inhibit replication of the new strain, at a concentration of 300 micromolar, according to preliminary research Darunavir, in conjunction with cobicistat, will be used in patients with COVID-19 pneumonia in trial number NCT04252274 (50). Such a mixture is currently approved by the United States Food and Drug Administration (FDA) in AIDS treatment. Darunavir is another HIV protease inhibitor and cobicistat, like ritonavir, is a booster to enhance the pharmacokinetics and pharmacodynamics of darunavir by inhibiting cytochrome P450 (CYP3A) [53] [54]. Due to in vitro evidence that supports its ability to fight this infection, Darunavir is being studied as a potential cure for SARS-CoV-2, the coronavirus responsible for COVID-19 [52]. Clinical trials are under progress and are scheduled to end in August 2020.
Several registered clinical trials are currently being conducted globally to evaluate the efficacy of the drugs against COVID-19 (Table-1)